โ Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (464) ๐ ๏ธ Industry Q&A (98) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
Date | Press release |
---|---|
2025-05-27 07:56:00 | Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics Basel, may 27, 2025 - novartis today announced that redwood merger sub inc., a delaware corporation and an indirect wholly owned subsidiary of novartis (โpurchaserโ), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the โsharesโ), of regulus therapeutics inc., a delaware corporation (โregulusโ), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a โcvrโ) per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. such offer is being made upon the terms and subject to the conditions set forth in the offer to purchase, dated may 27, 2025, and the related letter of transmittal (together, the โofferโ) and pursuant to the terms of the previously announced agreement and plan of merger, dated as of april 29, 2025 (the โmerger agreementโ), among novartis, purchaser and regulus. |
2025-05-15 09:00:00 | New Novartis Data At Asco And Eha Showcase Momentum Of Pioneering Portfolio With Promising Pipeline Basel, may 15, 2025 โ novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 american society of clinical oncology (asco) annual meeting and the european hematology association (eha) 2025 congress. |
2025-04-30 09:38:00 | Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, With Focus On Novartis In-depth adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. novartis ag leads, with north america as the largest market and asia-pacific fastest-growing. in-depth adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. novartis ag leads, with north america as the largest market and asia-pacific fastest-growing. |
2025-04-30 07:10:00 | Novartis To Acquire Regulus Therapeutics And Farabursen, An Investigational Microrna Inhibitor To Treat Adpkd, The Most Common Genetic Cause Of Renal Failure Basel, april 30, 2025 โ novartis today announced that it has entered into an agreement to acquire regulus therapeutics, a san diego-based, publicly traded (nasdaq: rgls) clinical-stage biopharmaceutical company focused on developing microrna therapeutics. regulusโ lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting mir-17 for the treatment of autosomal dominant polycystic kidney disease (adpkd). the agreed deal is fully in line with the therapeutic area focus of novartis and leverages our strength and expertise in renal disease. |
2025-04-30 07:00:00 | Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis Ag Novartis to acquire regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion transaction is expected to be completed in the second half of 2025, subject to customary closing conditions san diego , april 30, 2025 /prnewswire/ -- regulus therapeutics inc. (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the โcompanyโ or โregulusโ), today announced that it has entered into an agreement and plan of merger with novartis ag (โnovartisโ) and an indirectly wholly owned subsidiary of novartis, pursuant to which novartis will acquire regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. the upfront cash portion of the consideration represents a premium of 274 percent to regulusโ 60-day volume-weighted average stock price and 108 percent to regulusโ closing price on april 29, 2025. |
2025-04-02 20:29:00 |
|
2025-04-02 20:13:00 |
|
2025-03-31 01:00:00 |
|
2025-03-28 12:52:00 |
|
2025-03-25 02:15:00 |
|
2025-03-20 19:37:00 |
|
2025-03-20 19:11:00 |
|
2025-03-14 12:24:00 |
|
2025-03-13 08:03:00 |
|
2025-03-07 09:11:00 |
|

๐ฐ Browse additional press releases for Novartis!
Sign up for free or log in๐ Join now to get "The Checklist Value Investor โ A Smarter Way to Pick Stocks" at no cost